About US
Contact us
-
EC expands Takeda’s Adcetris authorisation for Hodgkin lymphomaThe European Commission (EC) has expanded the marketing authorisation of Takeda Pharmaceutical’s Adcetris (brentuximab vedotin) to adults with previously untreated CD30+ Stage IV Hodgkin lymphoma. Th2019/2/14
-
Novartis to divest Proleukin’s US rights to Clinigen for $210mNovartis has signed an agreement to divest the US rights to its Proleukin (aldesleukin) medicine to UK-based Clinigen Group for a total cash consideration of up to $210m. The transaction involves an2019/2/13
-
FDA grants Merck’s Keytruda priority review as first line therapy for HNSCCMerck has announced the US Food and Drug Administration (FDA) has granted priority review for its supplementary biologics license application (sBLA) for Keytruda as first line treatment for patients w2019/2/13
-
Samsung Bioepis forms new alliance to expand in ChinaSamsung Bioepis has signed a licensing deal with healthcare-focused private equity firm C-Bridge Capital to accelerate expansion in mainland China. The agreement involves the biopharmaceutical compan2019/2/12
-
Regeneron and Sanofi cut US list price of PraluentRegeneron and Sanofi have announced they have lowered the list price of high cholesterol drug Praluent (alirocumab) in the US by approximately 60%. The price for the drug will be lowered to $5,850 an2019/2/12
-
Mylan’s generic version of asthma drug Advair receives FDA approvalThe US Food and Drug Administration (FDA) has approved Mylan’s generic version of GlaxoSmithKline’s (GSK) asthma treatment Advair Diskus (fluticasone propionate and salmeterol inhalation powder). Dub2019/2/3
-
US Government’s new rule targets drug industry’s rebate systemUS Department of Health & Human Services (HHS) has proposed a new rule to end drug rebates and push direct discounts to patients across the country. The move is intended tolower the prices of pre2019/2/3
-
Merck obtains FDA breakthrough status for pneumococcal vaccineMerck has secured breakthrough designation from the US Food and Drug Administration (FDA) for its investigational 15-valent pneumococcal conjugate vaccine, V114. The company is developing the vaccine2019/2/2
-
Orphazyme publish good results for arimoclomol for NPCDanish drug maker Orphazyme has announced positive results from its Phase II/III trial of arimoclomol in rare genetic disease Niemann-Pick disease type C (NPC). The multi-centred, double-blind trial2019/2/2
-
Sanofi, Lilly and Novo face enquiry over high insulin prices in USDrug giants Sanofi, Eli Lilly and Novo Nordisk have been sent letters by US lawmakers requesting information on the increased costs of insulin in recent years and the companies’ profit from sales of t2019/2/1